Okomera

Okomera is developing a desktop platform for automated organoid screening using droplet-microfluidics and AI to accelerate drug discovery in oncology. Their patented technology, developed after 10 years of research, provides multiplexing, co-culture, and high-throughput screening of drug candidates on miniaturized Patient Derived Organoids (PDOs). This platform aims to improve the accuracy of disease models and the identification of new therapeutic targets.

Funding Round: Grant

Funding Amount:

Date: 21-Oct-2024

Investors: Bpifrance

Markets: Oncology, Drug Discovery, Biotechnology, Life Science, Therapeutics

HQ: Paris, Île-de-France, France

Founded: 2020

Website: https://www.okomera.com/

LinkedIn: https://www.linkedin.com/company/okomera

Twitter: https://twitter.com/Okomera1

Instagram:

Facebook: